Every manufacturing procedure results in the release of CO and other pollutants. A significant number of companies face a significant challenge when it comes to effectively reducing these emissions. MAN, Energy Solutions is developing new technologies that will support the extraction of a pure source of carbon monoxide (CO) from the emissions of your plant using a variety of different processes. We provide the technology for your process plant's heat recovery and heat integration, as well as the compression of CO/super-critical CO₂ and the liquefaction of CO₂. The process of compressing carbon dioxide makes it possible to store the gas in depleted oil fields or salty aquifers. Alternately, you may decide to convert the CO₂ into products that are of practical use in a plant that is located further down the production line as an alternative to sequestration. There is also the possibility of tank storage or truck transport. No matter which path you take, you can count on our remarkable selection of compressors to get the job done and produce the desired outcome. Consideration should be given to the possibility of safely capturing the carbon that is emitted during the production of major industrial commodities such as plastics and cement rather than merely concentrating on wholly decarbonizing these commodities, as is currently the case. The carbon capture and storage (CCS) process enables businesses to collect carbon at its point of origin, compress it, and transport it to a location that is suitable for long-term storage. Not only does the technology have the potential to significantly cut emissions of greenhouse gases, but it also has the potential to mean more money if the carbon dioxide can be used in a profitable manner to make other products. Manufacturers who use captured carbon to make plastics, such as polyurethane, are one of the many industries that are already working to put captured carbon dioxide to use in a profitable way. Other industries working towards the same goal include the chemical and energy industries. Emerging technologies, such as direct air capture, have historically been prohibitively expensive to implement at scale, which has prevented their widespread adoption

The study examined the synergistic impact of honey and lemon juice-enriched mulberry leaf diets on the silk gland growth and silk protein synthesis in Bombyx mori, together with the economic traits of sericulture.  Our study demonstrated that individually and synergistically, the honey and lemon juice-enriched mulberry diets have significantly enhanced the silk gland growth and larval body growth and their critical size determinants during the 7-day fifth instar larval regime, without altering their time schedules. The additional impetus given to larval growth has been extended to silk protein synthesis in the anterior, middle and posterior regions of the silk gland. The sericultural productivity, measured in terms of silk gland protein synthesis, cocoon traits like green cocoon weight, shell weight, floss weight, floss-shell ratio, shell protein content and floss protein content, silk traits like the raw silk weight, denier and renditta and the number of eggs produced by the female moth yielded positive gains under improved nutritional conditions.  Their positive impact of honey and lemon juice yielded a two-fold benefit to the sericultural industry. These two nutrients not only boosted the silk protein synthesis in all the three regions of the silk gland, but also reduced the synthesis of floss protein, which is considered to be a sericultural wastage. More importantly, their synergistic impact is more pronounced than that of their individual effects.

Chlorpromazine, commonly known as Thorazine and one of the embelin derivatives, was first synthesized in the early 1950s by French pharmacologist Henri Laborit and his colleagues. Chlorpromazine is produced by mixing 2-chloroacetophenone with dimethylamine, followed by further chemical alterations. revolutionized schizophrenia clinical care by catalyzing the development of psychopharmacology and standardized methodologies for monitoring antipsychotic clinical efficacy. Furthermore, chlorpromazine enhanced our understanding of the role of chemical signaling in neurotransmission while reducing the stigma associated with mental illness, enabling deinstitutionalization in the 1960s and 1970s. Because it was the first drug capable of treating symptoms of severe mental disease, the discovery of the chemical marked the beginning of a new era in psychiatric pharmacology. The synthesis of chlorpromazine was a game-changer in medicinal chemistry and pharmacology. It was the first pharmaceutical of its type to effectively lessen the symptoms of severe mental illnesses such as schizophrenia by modifying dopamine receptor activity in the brain. The synthesis of chlorpromazine paved the way for the development of further antipsychotic medicines, advancing understanding of the neurochemical basis of mental illnesses and revolutionizing psychiatric therapy. This Paper review will go through the synthesis, production, metabolism, pharmacokinetics, pharmacology, structure-activity relationship, and adverse effects of chlorpromazine. Finally, we examine the history and significant contributions of chlorpromazine, which have resulted in this powerful first-generation antipsychotic staying clinically relevant for more than 70 years.